Alyeska Investment Group
PACB icon

Alyeska Investment Group’s Pacific Biosciences PACB Stock Holding History

Alyeska Investment Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-908,107
Closed -$8.91M – 575
2023
Q4 		$8.91M Sell
908,107
-1,195,862
-57% -$9.78M 0.06% 269
2023
Q3 		$17.6M Buy
2,103,969
+174,883
+9% +$2M 0.12% 216
2023
Q2 		$25.7M Buy
1,929,086
+844,702
+78% +$10.3M 0.19% 164
2023
Q1 		$12.6M Buy
+1,084,384
New +$10.8M 0.11% 219
2022
Q4 		– Sell
-700,000
Closed -$4.06M – 489
2022
Q3 		$4.06M Buy
+700,000
New +$4.02M 0.05% 277
2022
Q1 		– Sell
-173,885
Closed -$3.56M – 644
2021
Q4 		$3.56M Sell
173,885
-221,439
-56% -$5.34M 0.04% 344
2021
Q3 		$10.1M Sell
395,324
-336,029
-46% -$9.96M 0.12% 195
2021
Q2 		$25.6M Buy
731,353
+406,353
+125% +$11.8M 0.3% 101
2021
Q1 		$10.8M Sell
325,000
-523,216
-62% -$18.3M 0.14% 190
2020
Q4 		$22M Sell
848,216
-651,784
-43% -$11.1M 0.31% 102
2020
Q3 		$14.8M Buy
+1,500,000
New +$8.64M 0.23% 141
2019
Q4 		– Sell
-1,281,676
Closed -$6.61M – 473
2019
Q3 		$6.61M Sell
1,281,676
-39,466
-3% -$221K 0.1% 195
2019
Q2 		$7.99M Sell
1,321,142
-628,858
-32% -$4.41M 0.1% 189
2019
Q1 		$14.1M Sell
1,950,000
-2,494,770
-56% -$18M 0.19% 145
2018
Q4 		$32.9M Buy
+4,444,770
New +$28.2M 0.48% 71
2017
Q3 		– Sell
-600,000
Closed -$2.14M – 518
2017
Q2 		$2.14M Buy
+600,000
New +$2.42M 0.02% 347
2017
Q1 		– Sell
-494,100
Closed -$1.88M – 536
2016
Q4 		$1.88M Buy
+494,100
New +$3.59M 0.02% 391

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Alyeska Investment Group's PACB Position: Q1 2024 in Review

Alyeska Investment Group sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 908,107 shares — an estimated $8.91M sold.

Alyeska Investment Group first reported a position in PACB in Q4 2016 and held it in 17 quarters. The position peaked at $32.9M in Q4 2018. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Alyeska Investment Group reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 908,107 Pacific Biosciences shares in Q1 2024, an estimated $8.91M.
  • Alyeska Investment Group first reported a position in Pacific Biosciences in Q4 2016 and held it in 17 quarters.
  • Alyeska Investment Group's Pacific Biosciences position peaked at $32.9M in Q4 2018.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.